newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

SER
  • Serina Therapeutics completed enrollment & dosing of all eight patients in Cohort 1 of its Phase 1b trial for SER-252 ahead of the previously disclosed end-of-third-quarter 2026 guidance.
  • Patients were dosed across clinical sites in the United States & Australia for the study evaluating SER-252 in patients with advanced Parkinson's disease.
  • An independent Safety Monitoring Committee will review Cohort 1 safety & tolerability data in accordance with the study protocol before determining the next dose-escalation step.
  • The company expects to provide a further update following the Safety Monitoring Committee's review.
  • The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose & multiple-ascending-dose components designed to evaluate safety, tolerability, & pharmacokinetics.
  • The study aims to assess exploratory efficacy measures including MDS-UPDRS motor scores & structured motor-state assessments in adults with Parkinson's disease & motor fluctuations.
  • Serina's POZ Platform utilizes a synthetic poly(2-oxazoline) polymer to improve drug loading control & release rate precision for subcutaneous injection.
  • SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation to reduce levodopa-related motor complications.
  • The company plans to expand the study to additional sites in South Korea & Taiwan.
  • Serina Therapeutics is headquartered in Huntsville, Alabama, & holds a non-exclusive license agreement with Pfizer, Inc. for its POZ polymer technology in lipid nanoparticle delivery.